Kornimate/medical-research-clean huggingface dataset:
peak tidal inspiratory flow in infants with moderate to severe acute viral bronchiolitis

Conditions: Bronchiolitis

Summary: this aim of this study is to measure the peak tidal inspiratory flow (ptif), using spirometry, in young infants with moderate to severe acute viral bronchiolitis (avb). ptif is important to consider for the management of avb with high flow nasal cannulae (hfnc). indeed, efficiency with hfnc is optimal provided that the settled flow is equal or higher than the patient's ptif. however, ptif values in infants with avb have never been determined.

hfnc allows the administration of a heated and humidified mixture of air and oxygen at high flows. this device has been widely adopted in pediatric intensive care units (picus) and for interhospital transport of critically ill children, as the system is easily set up and is well tolerated by patients. in the context of avb, retrospective audits and observational studies have suggested promising outcomes on both physiological and clinical variables. however, in less than 6 months old infants with moderate to severe avb, the failure rate with this device - defined as worsening of respiratory failure or the occurrence of discomfort or severe apnea - remains high, from 30% to 50% in key studies. hfnc flow setting remains empiric, 2 l/kg/min being used by most teams. a potential explanation for this high failure rate is that the flow usually used is lower than the patient's inspiratory flow. the aim of this study is to determine peak tidal inspiratory flow (ptif) values in infants up to 6 months old with moderate to severe avb. ptif will be evaluated with a spirometer connected to a face mask during 20 cycles of spontaneous ventilation. the measurements will be performed within the first 24 hours of hospitalization in the department of neonatal and pediatric intensive care of arnaud de villeneuve university hospital at montpellier (france). statistical analysis relation between the dip and silverman score, mwcas, rr, los will be expressed with parametric and non-parametric correlation coefficients according to the distribution of the data.

Eligibility criteria:
inclusion criteria: * infants up to 6 months old, with avb according to conventional clinical criteria; * admitted to the department of neonatal and pediatric intensive care at arnaud de villeneuve university hospital in montpellier (france); * supported with hfnc, according to the department's protocol (2 \< m-wcas \< 5); * not requiring immediate intubation for invasive ventilation; * signed parental consent. exclusion criteria: * infant with heart disease, cystic fibrosis or neuromuscular disorder; * infant requiring ventilatory support with nasal continuous positive pressure (ncpap) or with hfnc and without possibility of weaning, including for a few minutes; * intolerance of the spirometry mask.

Keywords: inspiratory flow high flow nasal cannula, spirometry spirometry physiologic study bronchiolitis patients sverity score mwcas/ 3-5.
effect of fibromyalgia on outcomes of transforaminal epidural steroid injection treatment in lumbar radicular pain

Conditions: Herniated Disk Lumbar; Fibromyalgia

Summary: lumbar radicular pain is defined as low back and leg pain caused by inflammation in the affected nerve root due to various etiological factors. in its treatment, there are various options such as anti-inflammatory drugs, physical therapy modalities, exercises, epidural steroid injections, and surgery. epidural steroid injections have also become a frequently applied method in the treatment of lumbar radicular pain unresponsive to conservative treatments. the steroid applied here acts by suppressing the inflammation around the affected nerve root. epidural steroid injections can be applied in lumbar radicular pain with 3 different approaches: caudal, interlaminar and transforaminal. in the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term. as far as we know, there is no previous study investigating the effect of fibromyalgia on tfese treatment outcomes. for this reason, the aim of our study is to examine the effect of fibromyalgia on treatment outcomes in patients who underwent tfese for lumbar radicular pain.


Eligibility criteria:
inclusion criteria: * findings of root compression on mri, lumbar radicular pain for at least 3 months, no previous history of lumbar spinal surgery, pain score of 4 and above according to the numerical rating scale (nrs), and acr 2016 diagnostic criteria for the fibromyalgia group were met. patients exclusion criteria: * patients who received lumbar epidural steroid injection in the last 3 months, who have pregnancy-breastfeeding, bleeding diathesis, contrast hypersensitivity, and patients who did not give consent for participation in the study

Keywords: fibromyalgia lumbar disc herniation tfese
glycemic emergency management (gem); an app for rapid response to hypoglycemic and hyperglycemic situations

Conditions: Diabetes Mellitus

Summary: the purpose of this pilot study is to determine the utility of an algorithm for better glucose control in diabetic patients communicated via an app to help improve outcomes and reduce urgent care and er visits as well as improve a1c and quality of life.

the aim of the study is to determine the impact of gem (glycemic emergency management device-app) in reducing the frequency and severity of hypoglycemia episodes in persons with diabetes. other objectives include: to determine whether the gem system leads to improved glucose control (as measured by hba1c) during participation in the pilot, to determine whether the gem can be used as a cost effective solution in reducing er and urgent care visits, to determine the difference in addqol scores between persons with a functioning gem system and those with a placebo device. the study hypothesis is as follows: there wil be significant differences in number of hypoglycemic events, er and urgent care visits, a1c, as well as quality of life as measured by the addqol scores between persons with diabetes who have the functioning gem device in their smart phones and those that do not have such a device installed in their smart phones. the purpose of this pilot study is to determine the utility of this application to help improve outcomes and reduce urgent care and er visits as well as improve a1c and quality of life in persons with diabetes. this approach may be a paradigm shift in the rapidly detecting, monitoring, intervening and managing the acute diabetic complications of hypoglycemia, hyperglycemia and diabetic ketoacidosis. spiraling health care costs are a major concern to the economy of the us. new measures have been introduced in the affordable care act to improve the efficiency of the health care delivery system. there is more emphasis on preventive health care services. our study is a step in that direction since it utilizes existing smart phone technology and converts it into a medical device which can be of invaluable help to the patient.

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes on therapeutic treatment other than just lifestyle changes * treatment by marshall internal medicine department * have a smart phone * at least 6th grade education level exclusion criteria: * pregnant women * cognitive impairment
study evaluating ism8207 in participants with advanced solid tumors and relapsed/refractory b-cell lymphoma

Conditions: Advanced Solid Tumors; Relapsed/Refractory B-cell Lymphoma

Summary: the goal of this clinical trial is to study ism8207 in participants with advanced solid tumors and relapsed/refractory b-cell lymphoma. the primary objective is to evaluate the safety and tolerability of ism8207 orally administered in participants with advanced solid tumors and relapsed/refractory b-cell lymphoma


Eligibility criteria:
inclusion criteria: 1. male or female participants with age ≥18 years at the time of signing the informed consent. 2. advanced solid tumors: histologically confirmed advanced or metastatic solid tumors who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists. b-cell lymphoma: histologically confirmed b-cell lymphoma who had received at least one prior line of standard therapy and were relapsed after or refractory to the standard therapy. 3. have measurable or evaluable lesions in part 1 and at least one measurable target lesion in part 2 as defined by response evaluation criteria in solid tumors (recist) criteria or lugano 2014. 4. ecog ps (eastern cooperative oncology group performance status)≤1. 5. life expectancy of ≥12 weeks as judged by the investigator. 6. adequate organ function as determined by medical assessment. 7. capable of providing signed icf and complying with the requirements and restrictions listed in the icf and in this study protocol. 8. female subjects of childbearing potential and male subjects must agree to use an effective method of contraception during the treatment period and for 90 days after the last dose of ism8207. exclusion criteria: 1. prior treated with other qpctl, cd47 or sirpα inhibitors. 2. burkitt lymphoma/leukemia, plasma cell myeloma, plasmablastic lymphoma. 3. participation in other therapeutic clinical studies within 28 days or 5 half- lives (whichever is shorter) prior to first dose of study treatment. 4. anti-tumor therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, or other anti-tumor therapy) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment. 5. previous allogeneic stem cell transplantation or autologous stem cell. transplantation within 3 months prior to first receiving study treatment. 6. unresolved toxicity of grade \>1 attributed to any prior therapies (excluding alopecia). 7. received antitumor steroid therapy within 7 days prior to the first study treatment administration. 8. a serious illness or medical condition(s)

Keywords: advanced solid tumors relapsed/refractory b-cell lymphoma lymphoma, b-cell
a study of combivir plus abacavir plus 141w94 in patients who previously have used anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to test the effectiveness of combivir plus abacavir plus 141w94 in patients who previously have used anti-hiv drugs.

in this open-label study antiretroviral-experienced patients receive combivir (3tc/azt tablet) plus 1592u89 (abacavir) and 141w94 twice daily for 48 weeks.

Eligibility criteria:
inclusion criteria patients must have: * cd4 count greater than 50 cells/mm3. * hiv rna less than 50,000 copies/ml. * no active aids (excluding cd4 count less than 200 cells/mm3). * ability to comply with dosing schedule and protocol evaluations. prior medication: allowed: azt or non-nucleoside reverse transcriptase inhibitors (nnrtis). exclusion criteria co-existing condition: patients with any of the following symptoms or conditions are excluded: * active aids (not excluding cd4 count less than 200). * malabsorption syndrome affecting drug absorption. * serious medical condition that would compromise safety of the patient. concurrent medication: excluded: * azt or nnrtis. * more than 1 week treatment with any protease inhibitor. * enrollment in any other investigational drug protocol. patients with the following prior conditions are excluded: history of clinically relevant pancreatitis or hepatitis within the past 6 months. required: antiretroviral therapy with either single or double reverse transcriptase inhibitors.

Keywords: drug therapy, combination patient compliance anti-hiv agents abacavir
pet (fdg)-mr imaging for the adult patients presented with brain tumor

Conditions: Brain Tumor

Summary: background and purpose: in adult, the half of the cns neoplasms are metastatic, and high grade astrocytomas and oligodendrogliomas are most frequent malignant tumors among the last half. recently, integrated mri-pet (biograph mmr, siemens, germany) was introduced, and can provide simultaneous whole body mri-pet imaging as well as brain-specific advanced imaging (e.g. dwi, pwi, and dce). the purpose of the present study is to evaluate whether the simultaneous mri-pet acquisition can improve the diagnostic yield for the patients initially presented with brain tumors, and predict the prognosis in the patients diagnosed with primary high graded astrocytoma or oligodendroglioma.

materials and methods: simultaneous mri-pet (fdg) will be prospectively obtained in patients (n = 60) initially presented with brain tumors by using integrated mri-pet (biograph mmr, siemens, germany). we will exclude the patients suspected to have benign brain tumors such as meningioma and schwannoma on previous imaging studies. we will use the imaging protocols including whole body mri-pet and advanced brain tumor imaging (dwi, pwi and dce). in addition, we will analyze the imaging parameters to see whether the enrolled tumors are primary brain tumors or metastatic, and evaluate the tumor grading efficiency and prognosis prediction for the patients with high grade astrocytomas or oligodendrogliomas. expected results: we expect that whole body mri-pet is useful for the differential diagnosis of primary and metastatic brain tumors, and the multiparametric information from dwi, pwi, dce and pet can be used for the tumor grading and prognosis prediction of the primary brain malignancies.

Eligibility criteria:
inclusion criteria: * we will inculude the enrolled tumors are primary brain tumors or metastatic, and evaluate the tumor grading efficiency and prognosis prediction for the patients with high grade astrocytomas or oligodendrogliomas. exclusion criteria: * we will exclude the patients suspected to have benign brain tumors such as meningioma and schwannoma on previous imaging studies.
nucleotides and b vitamins in the treatment of low back pain

Conditions: Low Back Pain

Summary: this is a double-blind, randomized study in parallel groups of subjects presenting with low back pain. randomized subjects will receive treatment for 60 days with either a combination of nucleotides and vitamin b12 or vitamin b1+b6+b12.

this is a double-blind, randomized study in parallel groups of subjects presenting with low back pain. randomized subjects will receive treatment for 60 days with either a combination of nucleotides and vitamin b12 or vitamin b1+b6+b12. the aim of this study is to evaluate and compare the therapeutic effect of the combination of nucleotides + vitamin b12 with that of the combination of vitamins b1, b6 and b12 in low back pain. safety and efficacy will be monitored throughout the treatment period. subjects will be randomized in a double-blind fashion to either treatment group.

Eligibility criteria:
inclusion criteria: * patients of both genders, at least 18 years of age * clinical presentation of acute lumbago (\<3 days of initial visit, with and without functional alteration, with medium intensity: visual analog pain score between 20mm and 80mm * female subjects should be post-menopausal or using birth control * subjects must sign informed consent document exclusion criteria: * intolerance to any component of the study treatments * pregnancy or breastfeeding * need for surgical treatment * use of other analgesic drugs * dyshematopoiesis or coagulation disorder * gastric or intestinal ulcer * gastrointestinal, cerebrovascular, or other bleeding * creatinine \>3x% reference range * urea, alt, ast, or ggt \>2x% reference range * any other disease or condition that in the investigator's opinion should exclude the subject from the study

Keywords: nucleotides (uridine, cytidine) vitamin b1 vitamin b6 vitamin b12
the association between food timing and composition on gastrointestinal injury, stress hormone and gastrointestinal complains.

Conditions: Endothelial Dysfunction

Summary: the study aimed to check the influence of timing and composition of diet on markers of gut injury, endotoxemia and stress.

the research protocol includes detailed food intake analysis, including timing and composition, markers related to the neuroendocrine pathway cortisol, and observations of individually experienced symptoms. moreover, the study also explores intestinal injury and endotoxemia parameters, such as i-fabp, cldn-3, and lbp. as a first goal, this study investigates the timing and composition of food intake concerning changes in gut integrity, cortisol levels, and gastrointestinal symptoms. investigators explored whether an athlete's nutritional intake influences any gi disturbance induced by high-intensity exercise. as a second goal, investigators tried to connect symptoms and markers from both pathways with gastrointestinal complaints. investigators hypothesised that cortisol levels would be more profound than other studied parameters in gastrointestinal symptoms.

Eligibility criteria:
inclusion criteria: * membership in polish rowing team, * minimum five years of training, * total training time minimum of 240 minutes, * filling out a food diary, * finishing 2000-meter ergometer test. exclusion criteria: * probiotics within the last three months, * prebiotics within the last three months * antibiotic therapy within the last three months, * dietary regime, * gastrointestinal diseases, * lactose intolerance

Keywords: athlete's diet endotoxemia cortisol gut injury gut permeability exercise
study of a novel non-invasive glucose monitoring device

Conditions: Diabetes Mellitus

Summary: this explorative clinical study has been launched to collect spectral raman data paired with validated glucose reference values in diabetic patients.

the investigational medical device (imd) for this investigation is the prototype 0.5 (p0.5) developed and manufactured by rsp systems (rsp). the device is intended for non-invasive interstitial intermittent glucose monitoring in persons (age 18 and older) with diabetes. the technology relies on the well-established capacities of raman spectroscopy for directly detecting glucose subcutaneously. the raman spectroscopy physical principle relies on the fact that when laser light of a given wavelength interferes with a molecule, a small fraction of the incident light will interact with the vibrational states of the molecule, causing the photons to lose a portion of their energy which will change the wavelength of the light. the scattered light will be collected by the optical probe head and analyzed with advanced algorithms to correlate the signal to glucose concentrations. data collected from the imd will be paired with validated glucose reference values collected by the finger sticking method.

Eligibility criteria:
inclusion criteria: * male and female subjects ≥18 years of age * diagnosed with diabetes, all types except gestational diabetes * hba1c distribution \> 60 mmol/mol at baseline visit * skin phototype 1-4 * willing to perform a minimum of 8 finger sticks during each day of home-based measurements and 30 finger sticks at the two in-clinic study days * subject has a wireless internet connection at home to be used in the study exclusion criteria: * for female subjects: pregnancy or subject is attempting to conceive or not willing and able to practice birth control during the study duration * for female subjects: breastfeeding * subject currently participating in another study * subject not able to understand and read danish * in investigator's opinion, subject is not able to follow instructions provided and as specified in the protocol * subject not able to hold hand/arm steady (including tremors and parkinson's disease) * reduced circulation in right hand evaluated by allen's test * extensive skin changes, tattoos or diseases on right hand thenar (probe application site) * known allergy to medical grade alcohol used to clean the skin * medical history or any condition that may, in the opinion of the investigator compromise the subject's ability to participate * comorbidity or concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff

Keywords: non-invasive glucose monitoring raman spectroscopy
virtual reality rehabilitation for stroke patients in the hospital and at home.

Conditions: Stroke Acute

Summary: the goal of this clinical trial is to test whether a low-cost virtual reality (vr) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. the study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits. the main questions it aims to answer are: * can vr-based motor therapy improve upper limb motor function compared to standard care? * is vr-based motor therapy a feasible and acceptable treatment option for stroke patients? researchers will compare patients receiving vr therapy to those receiving standard care to see if the vr therapy leads to greater improvements in motor recovery and more positive patient experiences. participants will: * complete standardized assessments of motor function and quality of life at multiple time points. * participate in vr therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement. * provide feedback on their experience with the vr system, including ease of use, motion sickness, and engagement. this study will help determine whether vr-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by ct or mri; * score between 6 and 40 on fugl-meyer assessment's upper limb extremity subscore (fm - ue), indicating moderate to severe motor deficit; * ability and willingness to provide consent (score of 18 or more on the montreal cognitive assessment) or assent (for scores lower than 18 on moca with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient) * inpatient arm: less than 5 weeks since stroke onset with admission to valley regional hospital in kentville, ns, canada * outpatient arm: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of valley regional hospital in kentville, ns, canada exclusion criteria: * brainstem, cerebellar or bilateral stroke lesion * a secondary neurological condition (e.g., parkinson's disease) * musculoskeletal injuries interfering with task performance * an uncorrected visual deficit due to stroke or other etiologies * apraxia as identified by clinical assessment

Keywords: stroke rehabilitation motor disorder virtual reality